SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001485003-16-000203
Filing Date
2016-12-06
Accepted
2016-12-06 16:37:05
Documents
5
Period of Report
2016-09-20
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A ebioform8kproformaviventia.htm 8-K/A 61248
2 EXHIBIT 23.1 exhibit23.htm EX-23.1 3113
3 EXHIBIT 99.1 viventiafs-fy153yearfinal.htm EX-99.1 462876
4 EXHIBIT 99.2 viventiafs-q216stubwxnotes.htm EX-99.2 269464
5 EXHIBIT 99.3 proformafinancialsviventia.htm EX-99.3 487692
  Complete submission text file 0001485003-16-000203.txt   1285538
Mailing Address 215 FIRST STREET SUITE 400 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 400 CAMBRIDGE MA 02142 617-871-9911
Eleven Biotherapeutics, Inc. (Filer) CIK: 0001485003 (see all company filings)

IRS No.: 252025616 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36296 | Film No.: 162036699
SIC: 2834 Pharmaceutical Preparations